TABLE 1

Scheme of Cohorts

Cohort	Patients (n)	TF2 dose (nmol)	Delay (h)	⁶⁸Ga-IMP288 dose and activity (nmol)	MBq	TF2/IMP288 molar dose ratio
I	3	120	24	6	150	20
II	3 + 9^{^*}	120	30	6	150	20
III	3 + 1^{^†}	120	42	6	150	20
IV	3	120	30	3	150	40
V	3	60	30	3	150	20

↵* Three patients in optimization phase of study and 9 in validation phase.
↵^† Patient 8 did not receive full hapten dose and was excluded and replaced for optimization phase study but was reintegrated for sensitivity study.